Novalead Pharma is a research company focused on discovery of new indications for existing drugs leveraging its in-house proprietary technology platform. Novaleads Drug Repositioning model offers a risk mitigated approach for discovering novel patent protected drugs. Lead candidate GalnobaxTM for diabetic foot ulcer has successfully completed Phase I/II a proof of concept global clinical trials. Now it is in Phase III in India. GalnobaxTM addresses a significant global unmet medical need with market size estimated well in excess of US$2 bn. Novalead is also working on a new indication pipeline of ten molecules across five disease areas.